Antithrombotic therapy: triple therapy or triple threat?

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Antithrombotic therapy is vital for managing prevalent and serious medical conditions.
• Triple oral antithrombotic therapy (TOAT) involves oral anticoagulation (OAC) plus dual antiplatelet therapy (DAPT).
• Current guidelines for TOAT primarily stem from observational data and older warfarin-based trials.

Purpose of the Study:

• To review the current landscape of triple oral antithrombotic therapy (TOAT).
• To explore the role of newer anticoagulant agents in TOAT regimens.
• To discuss the balance of efficacy and bleeding risks associated with TOAT.

Main Methods:

• Review of existing societal guidelines and clinical trial data.
• Analysis of studies involving warfarin and newer oral anticoagulants in patients requiring OAC and DAPT.
• Evaluation of pharmacokinetic properties and bleeding concerns associated with antithrombotic agents.

Main Results:

• Warfarin-based TOAT is associated with significant bleeding risks, partly due to its pharmacokinetic profile.
• Emerging data from recent trials using newer anticoagulants in atrial fibrillation and acute coronary syndromes offer insights into TOAT.
• The use of novel oral anticoagulants in TOAT requires further investigation to establish optimal use.

Conclusions:

• The established apprehension towards TOAT is largely due to bleeding concerns, particularly with warfarin.
• Newer anticoagulant agents present potential advantages over warfarin for TOAT.
• Individualized patient assessment, weighing bleeding and thrombotic risks, is essential for selecting the optimal antithrombotic strategy.